The European Medicines Agency (EMA) has just approved the administration to 12-17 year olds of the vaccine against Covid-19, Moderna. Until now, only the Pfizer vaccine had this authorization.
An antibody response comparable to that observed in 18-25 year olds
Moderna, the mRNA vaccine is the second most administered vaccine in France after Pfizer, with 6.368.384 (cumulative of first and second injections) people vaccinated according to CovidTracker. This is therefore one of the reasons why the American laboratory positioned itself at the beginning of June to request an authorization on our territory. According to a recent study conducted by the American biotechnology company published on May 25, the serum against Covid-19 is shown “Highly efficient”, that is, 93% among young people aged 12 to 17. Called TeenCOVE, the Moderna laboratory study involved more than 3 participants and “No concerns regarding his safety have been identified so far”, specifies the laboratory.
“The Committee for Medicinal Products for Human Use (…) of the AEM recommended to grant an extension of indication to the Covid-19 Spikevax vaccine (formerly Covid-19 Vaccine Moderna) to include its use in children aged 12 to 17 years “, said the European regulator in a press release.
Under the rise of the Delta variant, the Covid-19 pandemic is not ready to give up. In Europe its spread is around 26%, a figure that is likely to rise in the future and more than double in the next four weeks. The United States is also in this peak, with a spread of Covid-19 of around 60%.